According to Deutsche Bank, Amylin Pharmaceuticals AMLN Hold rating is maintained.
Deutsche Bank said that Amylin just announced that the FDA-required tQT study demonstrated that exenatide at and above therapeutic levels did not prolong QTc interval in healthy volunteers. “We currently believe AMLN shares are fairly valued at our $14 target price.”
Amylin Pharmaceuticals closed yesterday at $13.44.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in